U.S. Markets
CVS Health's (CVS) Caremark has finalized a settlement with US FTC in which it agreed to curb use of after-market discounts and count consumers' TrumpRx purchases toward their deductibles
StockNow breaking-news AI analysis
CVS Caremark finalized an FTC settlement to curb after-market discounts and count TrumpRx purchases toward deductibles. Analysts view the impact as manageable and a positive regulatory clearing event.
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.